Lyonbiopole is the one-stop shop for healthcare innovation in Rhône-Alpes.
Its aim
Support the emergence and developement of innovative technologies, products and services for a more personalized medicine to the patient’s benefit. Its four strategic areas are human medicine, veterinary medicine, in vitro diagnostics and medical devices and medical technologies.
Its positioning
Focusing on infectious diseases since its creation in 2005, Lyonbiopole is now supporting ambitious projects and companies in the fields of infectious diseases, cancer, nutrition, metabolic diseases and neurosciences.
Its role
Gathering a 176 member community
4 word class industrials as founders (Sanofi Pasteur, bioMérieux, Merial, BD),
154 innovative SMEs focused in healthcare
18 research centers
Its offer of support
Stimulate innovation
Support SMEs development
Strengthen the cluster’s international position
Develop a high-level infrastructure offer
Contact
Bâtiment Domilyon
321, avenue Jean Jaurès
69007 Lyon
Tel. : 04.72.76.53.30 – Fax : 09.55.91.30.26
Christophe Cizeron, president of Lyonbiopole, discusses the important economic and industrial position of the research cluster in the Rhone-Alps Region as well as the challenges posed by domestic and international…
Lyonbiopole was established in 2005 as a cluster designed to support the local business community focused on infectious diseases and microbiology. Philippe Archinard, the Biopole’s president, traces the evolution of…
As a majority of our readers are American that may be used to a different model of clusters can you explain the unique characteristics of the pôles de compétitivité? The…
Philippe Chêne, president of Winncare, highlights the key developments of the group over the past three years – most notably its acquisition of the UK player Mangar Health. Chêne goes…
Christine Placet, CEO of French biotech Horama, discusses the objective of becoming one of the key players in the field of ophthalmic gene therapy. She explains how Horama’s unique pipeline…
Thomas Clozel, co-founder and CEO of OWKIN, elaborates on how AI can be applied to the pharmaceutical industry to revolutionize today’s drug discovery and development process. He also comments on…
André Choulika, Chairman and CEO of Cellectis, discusses how UCART will revolutionize cell therapy as a universal gene-edited solution as opposed to the current therapies on the market which uses…
Bertrand L’Huillier, president of Smith & Nephew France, highlights how the medtech firm is able to understand the objectives and needs of hospitals better with a B2B approach. He also…
Claude Le Pen, a prominent healthcare economist and consultant for IQVIA, shares his view on the state of French and European social dynamics today and outlines the key trends shaping…
François Vorms, managing director of Canon Medical Systems France, shares the story of how the company navigated its transition from Toshiba to become a well-known player in the medical imaging…
Elie Lobel, CEO of Orange Healthcare, explains how digitalization is bringing together stakeholders from across the healthcare continuum, allowing increased information exchange and connectivity. Lobel also gives insight into the…
Eric Le Roy, director general of SNITEM (Syndicat National de l’Industrie des Technologies Médicales, The French National Association of the Medical Technologies Industry) discusses the profile of French medtech today,…
Vincent Pont, president of Laboratoire Arrow, explains the company’s history, its collaboration with Aurobindo, the Indian generic pharmaceuticals group, the company’s unique positioning as a leader in the generic hospital…
Bertrand de Lavenne, general manager of Mylan France, explains how the affiliate is positioned within the group’s operations and how the Mylan strategy is to be a key actor in…
Christophe Lala, general manager of western Europe for GE Healthcare offers an overview of the current dynamics impacting the French healthcare landscape – namely a shift in structure around care…
See our Cookie Privacy Policy Here
